President Donald Trump has signed a sweeping executive order aimed at compelling pharmaceutical companies to lower drug prices to match those in other countries. At a press conference, Trump emphasized the need for fairness, stating that Americans should not be paying significantly more than patients abroad.

The order sets a 30-day timeline for drugmakers to meet specific price targets, with a promise of further action if substantial progress isn’t made within six months. The pharmaceutical industry is pushing back, arguing that importing foreign pricing models could undermine innovation and limit patient access.

Trade groups warn the move could jeopardize future investment in American health care. As the administration prepares to implement the plan, the question remains: Can Trump successfully drive down drug prices, or will the challenge prove too great?

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.